NEO News and Press, NeoGenomics Inc. From 07/27/23

FT. MYERS, FL / ACCESSWIRE / July 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR® assay, a personalized liquid biopsy for minimal residual dis...

FT. MYERS, FL / ACCESSWIRE / July 18, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023. Company management will host a webc...

FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors. The Board has elected three new in...

FT. MYERS, FL / ACCESSWIRE / June 15, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that its RaDaR ® assay, a personalized liquid biopsy for minimal/molecular residual disease (MRD) and recurrence dete...

FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR® assay for the detection of molecular residual disease (MRD) and recurrence in patients ...

FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the company will be participating in the upcoming Goldman Sachs 44 th Annual Global Healthcare...

FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data supporting its cancer tests and treatment guidance tools will be showcased in five poster presentations at the 2023 A...

2023-05-18 14:00:44 ET Summary Today, we take our first look at NeoGenomics, Inc., a company focused on oncology testing. NeoGenomics has strung together a series of strong quarterly results that has helped the shares double so far in 2023. Still more upside, or time to "ring ...

2023-05-15 08:00:00 ET Summary China is the most important car market, about as big as the US and Europe combined. It is an essential market for several brands. EVs have a 25% market share of new Chinese sales, and, except Tesla, Western manufacturers play almost no role here. ...

2023-05-09 11:00:04 ET NeoGenomics ( NASDAQ: NEO ) added ~21% in the morning hours Tuesday as BTIG upgraded its shares to Buy from Neutral after the cancer-focused lab operator announced a strong topline beat and a guidance raise with its Q1 2023 results. With a $25 per ...